Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: An observational study from the Swedish national diabetes register

Journal of Hypertension

Volumn 28, Issue 10, 2010, Pages 2026-2035

  Cederholm, Jan ^a   Gudbjörnsdottir, Soffia ^b   Eliasson, Björn ^b   Zethelius, Björn ^a   Eeg Olofsson, Katarina ^b   Nilsson, Peter M ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

blood pressure; cardiovascular diseases; diabetes; hypertension,myocardial infarction; stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 77957259177     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833c8b75     Document Type: Article

References (33)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-444.
2. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412-419.
3. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Riskfactorsfor coronary arterydisease in noninsulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316:823-828.
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type-2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
5. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762. (Pubitemid 28269185)
6. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-259.
7. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med 2005; 165:1410-1419.
8. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. ADVANCE Collaborative Group Effects of a fixed combination of perindopril and indapamideon macrovascularand microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829-840.
9. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al., The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
10. Ryden L, Standl E, BartnikM, Van den Berghe G, Betteridge J, de Boer MJ, et al., The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007; 28:88136.
11. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115:114126.
12. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
13. Gudbjornsdottir S, Cederholm J, Nilsson PM, Eliasson B. The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care 2003; 26:1270-1276.
14. Nilsson PM, Cederholm J, Gudbjornsdottir S, Eliasson B, for the Steering Committee of the National Diabetes Register of Sweden. Predictors of successful long-term blood pressure control in patients with diabetes: prospective data from the National Diabetes Register (NDR) of Sweden. J Hypertens 2005; 23:2305-2311.
15. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, Gudbjornsdottir S. Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diabetes Care 2008; 31:2038-2043.
16. Gudbjornsdottir S, Eeg-Olofsson K, Cederholm J, Zethelius B, Eliasson B, Nilsson PM, on behalf of the NDR. Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR). Diabet Med 2009; 26:53-60.
17. Nilsson PM, Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Gudbjornsdottir S, et al., for the Swedish National Diabetes Register (NDR). Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: a report from the Swedish National Diabetes Register (NDR). Eur J Cardiovasc Prev Rehab 2009; 16:506-512.
18. Cederholm J, Zethelius B, Nilsson PM, Eeg-Olofsson K, Eliasson B, Gudbjornsdottir S, on behalf of the Swedish National Diabetes Register. Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Res Clin Pract 2009; 86:74-81.
19. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004; 50:166-174.
20. Merlo J, Lindblad U, Pessah-Rasmussen H, Hedblad B, Rastam J, Isacsson SO, et al. Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers. Eur J Epidemiol 2000; 16:235-243.
21. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A, Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90:583-612.
22. Ingelsson E, Sullivan LM, Fox CS, Meigs JB, D'Agostino RB, Wolf PA, et al. Burden and prognostic importance of subclinical cardiovascular disease in overweight and obese individuals. Circulation 2007; 116:375-384. (Pubitemid 47201828)
23. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al., ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global EndpointTrial study. J Hypertens 2009; 27:1360-1369.
24. Franklin SS. Isolated systolic hypertension and the J-curve of cardiovascular disease risk. Artery Res 2010; 4:1-6.
25. Cooper-Dehoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304:61-68.
26. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al., PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359:1225-1237.
27. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372:11 74-1183.
28. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144:884-893.
29. Bangalore S, Messerli FH, Wun C, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC, Treating to New Targets Steering Committee and Investigators. J-Curve revisited: an analysis of the Treating to New Targets (TNT) trial. J Am Coll Cardiol 2009; 53:A217.
30. The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
31. Redon J, Sleight P, Mancia G, Gao O, Verdecchia P, Fagard R, et al. Safety and efficacy of aggressive blood pressure lowering among patients with diabetes: subgroup analyses from the ONTARGET trial. J Hypertens 2009; 27 (Suppl 4):S16.
32. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829-840.
33. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1582.